title: Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?
abstract: This review focuses on the most recent literature concerning flow cytometry (FCM) application for diagnosis of myelodysplastic syndrome (MDS). Aberrant FCM results have been defined as abnormalities in at least three tested features comprising at least two bone marrow (BM) cell compartments. FCM results should be interpreted together with the BM smear cytology, the morphological assessment of BM biopsy, and cytogenetic results. Including FCM in the pre-treatment assessment may provide not only diagnostic but also prognostic information. Further studies are needed to evaluate the role of FCM in individual risk assessment for MDS patients and in therapy choice and/or follow-up.
authors.affiliation: Department of Pathobiology and Laboratory Medicine, , University Health Network, Toronto General Hospital, 200 Elizabeth Street, 11th Floor, R414, Toronto, ON, M5G 2C4, Canada, anna.porwit@uhn.ca.
authors.forename: Anna
authors.initials: A
authors.lastname: Porwit
mesh_terms: D000954:Antigens, Surface; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D016130:Immunophenotyping; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D010198:Pancytopenia / Q000175:diagnosis / Q000209:etiology; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000954:Antigens, Surface